Welcome to our dedicated page for Merus news (Ticker: MRUS), a resource for investors and traders seeking the latest updates and insights on Merus stock.
Merus N.V. (MRUS) generates frequent news as an oncology company focused on full-length human bispecific and trispecific antibody therapeutics, known as Multiclonics®. Its disclosures highlight clinical progress, regulatory designations, corporate transactions and collaboration updates that are relevant to investors and observers of the biotechnology sector.
A central theme in recent Merus news is the development of petosemtamab (MCLA-158), a Biclonics® antibody targeting EGFR and LGR5. Company announcements describe interim data from phase 2 trials in metastatic colorectal cancer, including combinations with FOLFOX and FOLFIRI and monotherapy in later-line settings, as well as data in recurrent or metastatic head and neck squamous cell carcinoma. News releases detail response rates, safety observations and presentations at major scientific meetings such as the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and the American Society of Clinical Oncology Annual Meeting.
Another important news stream concerns regulatory and strategic milestones. Merus has reported that the U.S. FDA granted Breakthrough Therapy Designation to petosemtamab in two head and neck cancer settings, and it has provided updates on phase 3 registration trials in first-line and later-line recurrent or metastatic HNSCC. In parallel, the company issues regular financial and business updates, including quarterly results, capital raises, and details on research collaborations with partners such as Incyte, Eli Lilly, Gilead, Ono and Biohaven.
Recent company announcements also cover the agreed acquisition of Merus by Genmab A/S through a cash tender offer and subsequent back-end transactions. Joint releases and 8-K filings describe the tender offer terms, acceptance levels, change of control and plans for a subsequent offering period. For users following MRUS news, this page offers a consolidated view of clinical, regulatory, financial and corporate developments, including the transition of Merus into an indirect wholly owned subsidiary of Genmab.
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology firm, announced that CEO Bill Lundberg will participate in a panel at Citi's 17th Annual BioPharma Conference on September 8, 2022, at 2:40 p.m. ET. This event highlights the company's innovative work in developing multispecific antibodies, including Biclonics® and Triclonics®. A live webcast will be available on the company’s investor page, and an archive of the presentation will be accessible for a limited time post-event.
For more details, visit Merus’ website and social media channels.
Merus N.V. (Nasdaq: MRUS) reported a strong clinical update for its lead bispecific antibody, zenocutuzumab (Zeno), demonstrating a 34% overall response rate in NRG1+ cancer patients at the 2022 ASCO meeting. The company anticipates MCLA-129 and petosemtamab (Peto) updates in late 2022 and early 2023, respectively. Financially, Merus ended Q2 2022 with $396.8 million in cash, enough to fund operations beyond 2024, while collaboration revenue increased to $12.7 million. However, operating losses rose, totaling $31.1 million for the quarter.
Merus N.V. (MRUS) announced interim data from the phase 1/2 eNRGy trial of its bispecific antibody, Zeno, aimed at treating NRG1+ cancer. Key findings include a 34% overall response rate in 79 evaluable patients, with a median duration of response at 9.1 months. Tumor reduction was observed in 70% of patients, and Zeno was noted to be well-tolerated. These results position Zeno as a potential new standard of care. An investor call is scheduled for June 5, 2022 to discuss these findings further.
Merus N.V. (Nasdaq: MRUS) will participate in a fireside chat at the Jefferies Healthcare Conference on June 10, 2022, at 12:45 p.m. ET. Bill Lundberg, M.D., the President and CEO, will represent the clinical-stage oncology company known for developing innovative multispecific antibodies, including Biclonics® and Triclonics®. A webcast of the event can be accessed on the Company's Investors page, and an archived version will be available post-event.
Merus N.V. (Nasdaq: MRUS) announced positive interim results from its phase 1/2 eNRGy trial of zenocutuzumab (Zeno) for NRG1+ cancers. The data shows a robust 34% overall response rate and a median duration of response of 9.1 months. The treatment is well-tolerated, with efficacy observed across multiple NRG1+ tumor types. An oral presentation is scheduled for June 5, 2022, at ASCO, with an investor call also planned the same day to discuss these findings. The trial focuses on safety and anti-tumor activity of Zeno monotherapy in various NRG1+ cancers.
Merus N.V. (Nasdaq: MRUS) announced that its CEO, Bill Lundberg, will present at the H.C. Wainwright Global Investment Conference. This presentation will occur on May 24, 2022, with a live webcast available at 7:00 a.m. ET on the company's Investors page. An archived version will be accessible for a limited time following the event.
Merus focuses on developing innovative full-length multispecific antibodies, including its proprietary Biclonics® and Triclonics® therapies, which have demonstrated promising features in clinical studies.
Merus N.V. (Nasdaq: MRUS) reported its Q1 2022 financial results, indicating a total revenue increase to $11.7 million from $8.4 million in Q1 2021, driven by collaboration revenue growth. The company ended Q1 with cash reserves of $384.3 million, down from $430.8 million at year-end 2021. Net loss for the quarter was $18.9 million, slightly improving from a loss of $10.2 million year-over-year. Merus is excited about its upcoming ASCO presentation on Zenocutuzumab, highlighting its ongoing clinical trials and pipeline growth. Cash runway is expected to last beyond 2024.
Merus N.V. (Nasdaq: MRUS) announced that an abstract showcasing interim clinical data for zenocutuzumab (Zeno), a bispecific antibody targeting NRG1+ cancer, has been selected for oral presentation at the 2022 ASCO Annual Meeting in Chicago from June 3-7, 2022. The presentation, titled 'Efficacy and safety of zenocutuzumab,' will take place on June 5. Merus is currently conducting the phase 1/2 eNRGy trial and will discuss updated interim data during a conference call on the same day.
Merus N.V. (Nasdaq: MRUS) announced the publication of a preclinical report on its bispecific antibody, petosemtamab (Peto, MCLA-158), in Nature Cancer. The report highlights Peto's potent growth inhibition of colorectal cancer organoids and its unique mechanism that triggers EGFR degradation in LGR5-expressing organoids. Peto shows promising results compared to cetuximab, with superior growth inhibition in KRAS mutant CRC models. The company is currently enrolling patients for a Phase 1 trial and plans a clinical update in the second half of 2022.
Merus N.V. (MRUS) announced promising preclinical data for MCLA-129, highlighting its ability to promote Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cell-Mediated Phagocytosis (ADCP) in non-small cell lung cancer (NSCLC). The findings, which show MCLA-129's significant inhibition of growth in a patient-derived EGFR exon20 insertion tumor model, will be presented at the AACR Annual Meeting 2022. Currently, MCLA-129 is in a phase 1/2 clinical trial, with updates anticipated in the second half of 2022.